Consequences of Sarcoidosis

Clinics in Chest Medicine

Volumn 36, Issue 4, 2015, Pages 727-737

  Drent, Marjolein ^a,b,c   Strookappe, Bert ^c,d   Hoitsma, Elske ^c,e   De Vries, Jolanda ^c,f,g  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c ild care foundation research team   (Netherlands)

^d GELDERSE VALLEI HOSPITAL   (Netherlands)

^e Alrijne Hospital   (Netherlands)

^f Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^g TILBURG UNIVERSITY   (Netherlands)

Author keywords

Cognitive impairment; Depressive symptoms; Exercise limitation; Fatigue; Pain; Quality of life; Rehabilitation; Sarcoidosis; Small fiber neuropathy

Indexed keywords

AMNESIA; ANXIETY; AUTONOMIC DYSFUNCTION; CARDIOPULMONARY EXERCISE TEST; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DYSPNEA; EXERCISE; FATIGUE; HUMAN; INTERPERSONAL COMMUNICATION; MEDICATION THERAPY MANAGEMENT; MENTAL STRESS; PATIENT PARTICIPATION; PHYSICAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION CARE; REVIEW; SARCOIDOSIS; SMALL FIBER NEUROPATHY; SYMPTOM; COGNITION DISORDERS; COMPLICATION; PAIN;

COGNITION DISORDERS; FATIGUE; HUMANS; PAIN; QUALITY OF LIFE; SARCOIDOSIS;

EID: 84947729201     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.08.013     Document Type: Review

References (89)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999, 160(2):736-755.
2. Valeyre D., Prasse A., Nunes H., et al. Sarcoidosis. Lancet 2014, 383:1155-1167.
3. De Vries J., Drent M. Quality of life and health status in sarcoidosis: a review of the literature. Clin Chest Med 2008, 29(3):525-532.
4. Judson M.A. Small fiber neuropathy in sarcoidosis: something beneath the surface. Respir Med 2011, 105(1):1-2.
5. Drent M., Lower E.E., De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012, 40(1):255-263.
6. Elfferich M.D., Nelemans P.J., Ponds R.W., et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010, 80(3):212-219.
7. Korenromp I.H., Heijnen C.J., Vogels O.J., et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011, 140(2):441-447.
8. Michielsen H.J., Peros-Golubicic T., Drent M., et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007, 74(4):401-405.
9. Baydur A., Alavy B., Nawathe A., et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 2011, 5(3):156-164.
10. De Kleijn W.P., Drent M., Vermunt J.K., et al. Types of fatigue in sarcoidosis patients. J Psychosom Res 2011, 71(6):416-422.
11. Sharma O.P. Fatigue and sarcoidosis. Eur Respir J 1999, 13(4):713-714.
12. Marcellis R.G., Lenssen A.F., de Vries J., et al. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013, 19(5):524-530.
13. Drent M., Marcellis R., Lenssen A., et al. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014, 31(2):117-128.
14. Morgenthau A.S., Iannuzzi M.C. Recent advances in sarcoidosis. Chest 2011, 139(1):174-182.
15. Cox C.E., Donohue J.F., Brown C.D., et al. Health-related quality of life of persons with sarcoidosis. Chest 2004, 125(3):997-1004.
16. Judson M.A., Costabel U., Drent M., et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014, 31(1):19-27.
17. Pereira C.A., Dornfeld M.C., Baughman R., et al. Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med 2014, 20(5):496-502.
18. Baughman R.P., Lower E.E., Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012, 41(6 Pt 2):e289-e302.
19. Michielsen H.J., Drent M., Peros-Golubicic T., et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006, 130(4):989-994.
20. Wirnsberger R.M., de Vries J., Breteler M.H., et al. Evaluation of quality of life in sarcoidosis patients. Respir Med 1998, 92(5):750-756.
21. Hoitsma E., De Vries J., Drent M. The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir Med 2011, 105(1):95-100.
22. Hinz A., Fleischer M., Brahler E., et al. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011, 33(5):462-468.
23. De Vries J., Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21(1):57-63.
24. Korenromp I.H., Grutters J.C., van den Bosch J.M., et al. Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones. J Psychosom Res 2012, 72(2):97-102.
25. Verbraecken J., Hoitsma E., van der Grinten C.P., et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21(2):137-146.
26. Baughman R.P., Sparkman B.K., Lower E.E. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007, 132(1):207-213.
27. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164(10 Pt 1):1885-1889.
28. Marcellis R.G., Lenssen A.F., Elfferich M.D., et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011, 38(3):628-634.
29. Judson M.A., Baughman R.P., Thompson B.W., et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(3):204-211.
30. Baughman R.P., Judson M.A., Teirstein A., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006, 99(5):307-315.
31. Hoitsma E., Marziniak M., Faber C.G., et al. Small fibre neuropathy in sarcoidosis. Lancet 2002, 359(9323):2085-2086.
32. Bakkers M., Merkies I.S., Lauria G., et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009, 73(14):1142-1148.
33. Hoitsma E., Drent M., Verstraete E., et al. Abnormal warm and cold sensation thresholds suggestive of small-fibre neuropathy in sarcoidosis. Clin Neurophysiol 2003, 114(12):2326-2333.
34. Hoitsma E., Reulen J.P., de Baets M., et al. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004, 227(1):119-130.
35. Hoitsma E., Drent M., Sharma O.P. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 2010, 16(5):472-479.
36. Tavee J., Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med 2009, 76(5):297-305.
37. Hoitsma E., Faber C.G., Drent M., et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004, 3(7):397-407.
38. Tavee J., Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011, 15(3):201-206.
39. Katon W., Lin E.H., Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007, 29(2):147-155.
40. Freeman R., Komaroff A.L. Does the chronic fatigue syndrome involve the autonomic nervous system?. Am J Med 1997, 102(4):357-364.
41. Korenromp I.H., Grutters J.C., van den Bosch J.M., et al. Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue. Brain Behav Immun 2011, 25(7):1498-1502.
42. Kim Y.K., Na K.S., Shin K.H., et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(5):1044-1053.
43. Chang B., Steimel J., Moller D.R., et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001, 163(2):329-334.
44. De Vries J., Rothkrantz-Kos S., van Dieijen-Visser M.P., et al. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21(2):127-136.
45. Drent M., Wirnsberger R.M., Breteler M.H., et al. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998, 15(1):59-66.
46. Elfferich M.D., De Vries J., Drent M. Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28(1):65-71.
47. de Kleijn W.P., Drent M., De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol 2013, 18(2):439-452.
48. Ireland J., Wilsher M. Perceptions and beliefs in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27(1):36-42.
49. Hinz A., Brähler E., Möde R., et al. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012, 29:139-146.
50. Spruit M.A., Janssen D.J., Franssen F.M., et al. Rehabilitation and palliative care in lung fibrosis. Respirology 2009, 14(6):781-787.
51. Goracci A., Fagiolini A., Martinucci M., et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry 2008, 30(5):441-445.
52. Holas P., Krejtz I., Urbankowski T., et al. Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013, 30(4):282-288.
53. de Boer S., Kolbe J., Wilsher M.L. The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology 2014, 19(7):1019-1024.
54. Yamada Y., Tatsumi K., Yamaguchi T., et al. Influence of stressful life events on the onset of sarcoidosis. Respirology 2003, 8(2):186-191.
55. Klonoff E.A., Kleinhenz M.E. Psychological factors in sarcoidosis: the relationship between life stress and pulmonary function. Sarcoidosis 1993, 10(2):118-124.
56. Chaturvedi S.K., Peter Maguire G., Somashekar B.S. Somatization in cancer. Int Rev Psychiatry 2006, 18(1):49-54.
57. Shin S.Y., Katz P., Wallhagen M., et al. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res 2012, 64(8):1144-1150.
58. Jougleux-Vie C., Duhin E., Deken V., et al. Does fatigue complaint reflect memory impairment in multiple sclerosis?. Mult Scler Int 2014, 2014:692468.
59. Swigris J.J., Brown K.K., Make B.J., et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 2008, 102(12):1675-1680.
60. Marcellis R.G., Lenssen A.F., Kleynen S., et al. Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study. Lung 2013, 191(3):247-256.
61. Spruit M.A., Thomeer M.J., Gosselink R., et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005, 60(1):32-38.
62. Baughman R.P., Lower E.E. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007, 13(5):439-444.
63. Wallaert B., Talleu C., Wemeau-Stervinou L., et al. Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. Respiration 2011, 82(6):501-508.
64. Wirnsberger R.M., Drent M., Hekelaar N., et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997, 10(7):1450-1455.
65. Barros W.G., Neder J.A., Pereira C.A., et al. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004, 71(4):367-373.
66. Medinger A.E., Khouri S., Rohatgi P.K. Sarcoidosis: the value of exercise testing. Chest 2001, 120(1):93-101.
67. Marcellis R.G., Lenssen A.F., de Vries G.J., et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?. Lung 2013, 191(1):43-52.
68. Braam A.W., de Haan S.N., Vorselaars A.D., et al. Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis. Brain Behav Immun 2013, 33:57-64.
69. Marcellis R.G., Veeke M.A.F., Mesters I., et al. Does physical training reduce fatigue in sarcoidosis?. Sarcoidosis Vasc Diffuse Lung Dis 2015, 32(1):53-62.
70. Strookappe E.W., Elfferich M.D.P., Swigris J.J., et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015, 32(1):43-52.
71. De Vries J., Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med 2007, 28(1):121-127.
72. Thomten J., Soares J.J., Sundin O. The influence of psychosocial factors on quality of life among women with pain: a prospective study in Sweden. Qual Life Res 2011, 20(8):1215-1225.
73. Patel A.S., Siegert R.J., Creamer D., et al. The development and validation of the King's sarcoidosis questionnaire for the assessment of health status. Thorax 2013, 68(1):57-65.
74. Holtzman S., Newth S., Delongis A. The role of social support in coping with daily pain among patients with rheumatoid arthritis. J Health Psychol 2004, 9(5):677-695.
75. Goldberg G.M., Kerns R.D., Rosenberg R. Pain-relevant support as a buffer from depression among chronic pain patients low in instrumental activity. Clin J Pain 1993, 9(1):34-40.
76. Dysvik E., Lindstrom T.C., Eikeland O.J., et al. Health-related quality of life and pain beliefs among people suffering from chronic pain. Pain Manag Nurs 2004, 5(2):66-74.
77. Marhold C., Linton S.J., Melin L. Identification of obstacles for chronic pain patients to return to work: evaluation of a questionnaire. J Occup Rehabil 2002, 12(2):65-75.
78. De Vries J., Wirnsberger R.M. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon 2005, 32:92-104.
79. Parambil J.G., Tavee J.O., Zhou L., et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011, 105(1):101-105.
80. Wijnen P.A., Cremers J.P., Nelemans P.J., et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014, 43(6):1730-1739.
81. Holland A.E., Hill C.J., Conron M., et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008, 63(6):549-554.
82. Spruit M.A., Wouters E.F.M., Gosselink R. Rehabilitation programmes in sarcoidosis: a multidisciplinary approach. Eur Respir J 2005, 32:316-326.
83. Swigris J.J., Fairclough D.L., Morrison M., et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care 2011, 56(6):783-789.
84. Boots A.W., Drent M., de Boer V.C., et al. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 2011, 30(4):506-512.
85. Boots A.W., Drent M., Swennen E.L., et al. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir Med 2009, 103(3):364-372.
86. Strookappe B., Swigris J., De Vries J. Benefits of physical training in sarcoidosis. Lung 2015, [Epub ahead of print].
87. van Osch M., Sep M., van Vliet L.M., et al. Reducing patients' anxiety and uncertainty, and improving recall in bad news consultations. Health Psychol 2014, 33(11):1382-1390.
88. Derksen F., Bensing J., Kuiper S., et al. Empathy: what does it mean for GPs? A qualitative study. Fam Pract 2015, 32(1):94-100.
89. Drent M. Sarcoidosis: benefits of a multidisciplinary approach. Eur J Intern Med 2003, 14(4):217-220.